Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Earnings data Q1 2024

Rani Therapeutics excels in drug delivery innovation and clinical trials

Rani Therapeutics showcased strong performance in drug delivery innovation and promising clinical trial results. While facing challenges in partnerships and program prioritization, the company is well-positioned to capitalize on opportunities for pipeline expansion and strategic collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m.

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's shareholders.  The investigation seeks to determine whether Rani Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Rani Therapeutics's stock price.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock

- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024 - - Initiation of Phase 2 clinical trial of RT-102, a RaniPill GO containing teriparatide for osteoporosis, expected by the year-end 2023 - - Announced RaniPill capsule was well-tolerated in 60-day, repeat oral-administration GLP safety study - - Announced successful drug delivery with RaniPill HC high-capacity capsule in multiple preclinical studies with cumulative >90% success rate - SAN JOSE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada.

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

RANI is developing a payload agnostic robotic pill (RaniPill) with enormous potential for penetration of several multi-billion injectable drug delivery markets. Pre-clinical and early-phase human studies consistently show effective and safe oral delivery of various molecules, including larger antibody-based biological therapies like adalimumab. Being an early-stage biotech, there are major risks, including fierce competition, challenged patents and low cash balance.

Rani Therapeutics: Excellent Technology But Major Risks Ahead

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered RaniPill®GO capsule containing an ustekinumab biosimilar, CT-P43.

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participate in and present at two upcoming investor conferences in September 2023. These conferences include:

Rani Therapeutics to Participate in September Investor Conferences

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update.

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:

Rani Therapeutics to Participate in August Investor Conferences

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that its abstract entitled “An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers the Human Parathyroid Hormone Analog hPTH (1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study,” presented on June 17 by Joshua Myers, Director of Clinical Operations at Rani, won the Presidential Poster Competition in the Bone and Mineral Metabolism category at the 105th annual meeting of The Endocrine Society (ENDO 2023). The Endocrine Society committee recognized Rani for its exceptional scientific work on RT-102, the company's oral robotic RaniPill® delivering teriparatide, or parathyroid hormone (PTH) (1-34), which is being developed as an oral osteoanabolic therapy for osteoporosis.

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that a late-breaking abstract “Oral Delivery of a GLP-1 Agonist with High Bioavailability in Dogs and Humans” has been selected for poster presentation at the American Diabetes Association's (ADA) Scientific Sessions taking place on June 23 - 26, 2023 in San Diego, CA.

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111 This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

SAN JOSE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company's Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 from 4:00-4:25 pm E.T. in Track 3.

Rani Therapeutics to Present at the Jefferies Healthcare Conference

SAN JOSE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that three submitted abstracts were accepted for poster presentations at the 105th annual meeting of The Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago, Illinois.

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer.

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

- Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab -

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. has an exciting oral drug delivery system for biologics. It has shown excellent early data in trials.

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company's Chief Executive Officer, Talat Imran, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 12:45 p.m. PT / 3:45 p.m. ET.

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group LLC Talat Imran - CEO Svai Sanford - CFO Mir Hashim - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Hao Shen - Bank of America Andreas Argyrides - Wedbush Annabel Samimy - Stifel Ashwani Verma - UBS Bert Hazlett - BTIG Mitchell Kapoor - H. C. Wainwright Operator Hello, and welcome to Rani Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call.

News for Rani Therapeutics Holdings Stock (RANI)